Latest Updates
4/1/2021 - HCV Management in Special Populations
4/1/2021 - HCV Management in Special Populations
4/1/2021 - HCV Management in Special Populations
4/1/2021 - HCV Management in Special Populations
4/1/2021 - HCV Management in Special Populations
4/1/2021 - HCV Management in Special Populations
1/9/2021 - Management of HCV Infection
1/9/2021 - Management of HCV Infection
1/9/2021 - Management of HCV Infection
10/30/2020
-
Hepatitis C Virus Epidemiology, Pathogenesis, Diagnosis, and Natural History
- Updated data on US prevalence of HCV infection
- Recent data on the transplant of organs from HCV-viremic donors to recipients without HCV infection
- Updated IDU prevalence rates and data on the effectiveness of HIV prevention programs for reducing transmission of HCV
- Recent data on HCV reinfection rates among patients with recent drug use and in those receiving opioid agonist therapy
- Updated guidelines on testing for HCV in infants born to mothers infected with HIV
- Updated guidance on when to use barrier protection during sexual intercourse to prevent sexual transmission
- Updated guidance on HCV screening
- Inclusion of a new serologic immunoassay approved by the FDA for the detection of HCV
- Updated data and considerations for primary care physicians
10/29/2020
-
HCV Management in Special Populations
- Updated based on revised AASLD/IDSA and EASL guidelines:
- Removal of less efficacious, complex, and alternative regimens and ones no longer available in the United States
- New treatment regimens for children 3-11 years of age
- Update on recommended regimens for patients who experienced treatment failure with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir
- Updated treatment regimens for recurrent HCV in the posttransplantation setting
- Removal of less efficacious, complex, and alternative regimens and ones no longer available in the United States
- New treatment regimens for children 3-11 years of age
- Update on recommended regimens for patients who experienced treatment failure with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir
- Updated treatment regimens for recurrent HCV in the posttransplantation setting
8/17/2018 - HCV Management in Special Populations
8/17/2018 - HCV Management in Special Populations
8/17/2018 - HCV Management in Special Populations
8/17/2018 - HCV Management in Special Populations
8/17/2018 - HCV Management in Special Populations
8/17/2018 - HCV Management in Special Populations
8/17/2018 - HCV Management in Special Populations
8/17/2018 - HCV Management in Special Populations
8/17/2018 - HCV Management in Special Populations
7/24/2018 - Management of HCV Infection
7/24/2018 - Management of HCV Infection
7/24/2018 - Management of HCV Infection
7/24/2018 - Management of HCV Infection
7/24/2018 - Management of HCV Infection
7/24/2018 - Management of HCV Infection
5/23/2018
-
Hepatitis C Virus Epidemiology, Pathogenesis, Diagnosis, and Natural History
- Updated data on global prevalence of HCV infection
- New data on HCV transmission via organ transplant from seropositive, NAT-negative donors
- Updated IDU prevalence rates and reinfection risk estimates
- Recent studies on HCV sexual transmission highlight risk factors among women sex workers and MSM
- New data on HCV seroprevalence and reinfection risk among incarcerated persons
- Latest risk-based guidance on anti-HCV screening
- HCV testing algorithm for follow-up of individuals testing anti-HCV positive
- Currently available assays for HCV RNA detection and guidance on interpreting assay results
- Recent data on risk factors for and rate of liver biopsy-associated complications
- Updated data on primary HCV infection in the United States
5/9/2018
-
Management of HCV Infection
- New guidance on clinical strategies to reduce risk of HCV reinfection among at-risk populations, including persons who inject drugs, HIV-coinfected men who have sex with men, and individuals in correctional settings
- Updated data from phase II C-SCAPE and phase III C-EDGE TE of elbasvir/grazoprevir ± ribavirin in treatment-naive and treatment-experienced patients
- Updated data from phase III ENDURANCE-1 trial of 8- vs 12-week courses of glecaprevir/pibrentasvir in noncirrhotic patients with genotype 1 HCV, including HIV coinfection
- Updated real-world data for ledipasvir/sofosbuvir-containing regimens in patients with genotype 1 HCV
11/21/2017 - Management of HCV Infection
9/28/2017 - Management of HCV Infection
5/25/2017
-
Management of HCV Infection
- Updated AASLD/IDSA guidance on initial HCV treatment now recommends 8-week
ledipasvir/sofosbuvir for treatment-naive nonblack patients with genotype 1 HCV infection, no cirrhosis, no HIV coinfection, and baseline HCV RNA < 6 million IU/mL
- Revised AASLD/IDSA guidance on retreatment of genotype 3 HCV infection
7/24/2015
-
Hepatitis C Virus Epidemiology, Pathogenesis, Diagnosis, and Natural History
- Updated global epidemiologic data from the CDC
- Data suggesting rate of reinfection among IDUs low after treatment with antiviral therapy
- Interferon-free regimens provide means of treating HCV-related autoimmune conditions with contraindications to interferon
- Study suggesting no association between HCV and diabetes in US population
- New data demonstrating predominant role of host genetic variants in MHC in accelerated liver fibrosis
- Updated to reflect current guidance from EASL
2/25/2014 - Hepatitis C Virus Epidemiology, Pathogenesis, Diagnosis, and Natural History
Updated to include revised guidelines from the AASLD/IDSA on the following topics:
- Situations where barrier protection during intercourse is recommended to prevent sexual transmission of HCV
- HCV testing recommendations for persons with tattoos received in unregulated settings
- Counseling patients with HCV infection on measures to prevent transmission to others
- Birth cohort and risk-based screening for HCV infection
- Serologic assays for initial detection of HCV infection
- HCV RNA testing
- Strategies for assessing liver disease in patients with HCV infection